|
Baseline trial characteristics
|
|
ID
|
Valid PubMed ID number
|
Pubmed ID
|
|
Journal
|
Name of journal
|
Journal of publication
|
|
Year
|
2007–2018
|
Year of publication
|
|
Tumor site
|
Non-small cell lung cancer Melanoma Renal cell carcinoma Squamous cell carcinoma of the head and neck Urothelial carcinoma Classical Hodgkin lymphoma Other
|
The tumor type for which treatment with a check-point inhibitor was analyzed.
|
|
Check_point_1
|
Nivolumab
|
Name of the first check-point inhibitor being compared.
|
|
Pembrolizumab
|
|
Atezolizumab
|
|
Avelumab
|
|
Durvalumab
|
|
Ipilimumab
|
|
Tremelimumab
|
|
Check_point_2
|
Nivolumab
|
Name of 2nd check-point inhibitor being compared, if applicable.
|
|
Pembrolizumab
|
|
Atezolizumab
|
|
Avelumab
|
|
Durvalumab
|
|
Ipilimumab
|
|
Tremelimumab
|
|
Comparator_1
|
Placebo
|
Name of the 1st non-check-point-inhibitor agent or chemotherapeutic regimen being compared, if applicable.
|
|
Name of other agent or regimen
|
|
Comparator_2
|
Placebo
|
Name of the 2nd non-check-point-inhibitor agent or chemotherapeutic regimen being compared, if applicable.
|
|
Name of other agent or regimen
|
|
Funding
|
Industry/government
|
Funding source declared by article
|
|
Country
|
List of country names
|
List of all the countries in which the economic analysis applied as reported by the article.
|
|
Multiple_countries
|
Y/N
|
Did the economic analysis apply to multiple countries?
|
|
CHEERS criteria
|
|
Title
|
C/I
|
As detailed in CHEERS recommendations [9]
|
|
Abstract
|
C/PC/I
|
As detailed in CHEERS recommendations [9]
|
|
Background & Objectives
|
C/PC/I
|
As detailed in CHEERS recommendations [9]
|
|
Target population
|
C/PC/I
|
As detailed in CHEERS recommendations [9]
|
|
Setting_Location
|
C/PC/I
|
As detailed in CHEERS recommendations [9]
|
|
Perspective
|
C/PC/I
|
As detailed in CHEERS recommendations [9]
|
|
Comparators
|
C/PC/I
|
As detailed in CHEERS recommendations [9]
|
|
Time horizon
|
C/PC/I
|
As detailed in CHEERS recommendations [9]
|
|
Discount rate
|
C/PC/I
|
As detailed in CHEERS recommendations [9]
|
|
Health outcomes
|
C/PC/I
|
As detailed in CHEERS recommendations [9]
|
|
Effectiveness
|
C/PC/I
|
As detailed in CHEERS recommendations [9]
|
|
Preference for outcomes
|
C/PC/I/NA
|
As detailed in CHEERS recommendations [9]
|
|
Resources and cost
|
C/PC/I
|
As detailed in CHEERS recommendations [9]
|
|
Resource quantities
|
C/PC/I
|
As detailed in CHEERS recommendations [9]
|
|
Choice of model
|
C/PC/I
|
As detailed in CHEERS recommendations [9]
|
|
Assumptions
|
C/PC/I
|
As detailed in CHEERS recommendations [9]
|
|
Analytic methods
|
C/PC/I
|
As detailed in CHEERS recommendations [9]
|
|
Study parameters
|
C/PC/I
|
As detailed in CHEERS recommendations [9]
|
|
ICERs
|
C/PC/I
|
As detailed in CHEERS recommendations [9]
|
|
Uncertainty
|
C/PC/I
|
As detailed in CHEERS recommendations [9]
|
|
Heterogeneity
|
C/PC/I/NA
|
As detailed in CHEERS recommendations [9]
|
|
Limitations
|
C/PC/I
|
As detailed in CHEERS recommendations [9]
|
|
Funding source
|
C/I
|
As detailed in CHEERS recommendations [9]
|
|
Conflict of Interest
|
C/I
|
As detailed in CHEERS recommendations [9]
|
